Skip to main content

Table 4 Prognostic factors for overall survival (OS) and progression-free survival (PFS) after stereotactic brachytherapy (SBT)

From: Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas

Prognostic factor

No

% 5-/10-years OS

% 5-/10-years PFS

p-value OS/PFS

Sex

   

0.45/0.50

Female

47

85/59

52/35

 

Male

59

71/50

40/26

 

Age at first SBT

   

0.68/0.55

< 40 years

50

79/59

46/25

 

> 40 years

56

75/50

44/34

 

Tumor volume at SBT in ml

   

0.15/0.44

< 10 ml

55

83/63

53/41

 

> 10 ml

56

66/30

26/14

 

Histology

   

0.75/0.06

Astrocytoma

90

76/54

47/31

 

Oligoastrocytoma/Oligodendroglioma

16

79/57

28/–

 

MGMT methylation

   

0.73/0.80

Yes

42

87/53

37/–

 

No

9

75/–

50/–

 

LOH 1p/19q

   

0.27/0.82

Yes (= loss of either or both)

20

94/74

52/–

 

No

27

76/40

37/20

 
  1. OS, overall survival; PFS, progression-free survival; No, number; SBT, stereotactic brachytherapy; LOH, loss of heterozygosity; MGMT methylation, o-6methylguanine-DNA methyltransferase methylation